Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Indivior

This common antidepressant helps people cut back on methamphetamine – new study

Methamphetamine – more commonly known as meth, crystal or ice – is a highly addictive, stimulant drug.

The Conversation

GLP-1 drugs like Ozempic may lower the risk of addiction: new study

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction – and help people who already have one, a new study shows.

The Conversation

Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher

Virginia-based Indivior, a developer of opioid addiction treatments, continues to hold down a place in Barchart’s Top 100 Stocks to Buy. Up 192% in 2025, its P/E is declining despite the stock’s gains over the past year. Here’s why.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Top 100 Stocks to Buy: Indivior Advances Into Top 50 on Momentum

In Monday’s trading, the opioid-treatment pharmaceutical company’s stock moved into the top 50 in Barchart’s Top 100 Stocks to Buy in 46th position, up 11 spots from Friday. With profits rising, it’s got momentum on its side.

Barchart

The Street Loves This ‘Strong Buy’ Pharma Stock

Indivior (INDV) is up 90% since April and has consistently hit new highs, driven by optimism for Sublocade. INDV stock set its latest 52-week high in morning trading on Aug. 8. Technical indicators are overwhelmingly bullish. Indivior has a 100% “Buy” rating from Barchart. Despite the current momentum, INDV is...

Barchart

Drugmaker Indivior to abandon London listing amid exodus of companies

Firm behind opioid addiction treatment drugs quits London Stock Exchange after moving primary to US last year

The Guardian - UK

Drug maker Indivior to abandon London stock market for the US

Indivior’s exit comes after the company moved its primary listing to the US’s Nasdaq index last year.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Drug maker Indivior joins the flight from London share listings

Pharmaceuticals company said most of its product sales and shareholders are US based

Evening Standard

Flutter shareholders vote to move listing from London to New York

Paddy Power owner will make switch to its ‘natural home’ by May in further blow to London Stock Exchange

The Guardian - UK

Drug firm Indivior plans to move primary listing to US in snub to London

Move is latest in number of delistings and IPO snubs to London Stock Exchange, including Tui

The Guardian - UK

UK borrowing costs hit new 25-year high; Chinese stocks fall to pre-pandemic level – as it happened

Rolling, live coverage of business, economics and financial markets as British bond yields rise amid expectations of stubbornly high interest rates

The Guardian - UK

Maker of anti-addiction drug Suboxone reaches $102.5 million settlement over antitrust claims

The company that makes the opioid addiction treatment drug Suboxone has reached a $102.5 million settlement of antitrust claims with 41 states and the District of Columbia

The Independent UK

A new nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval

WEKU

New nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval

U.S. health regulators have approved a new nasal spray to reverse overdoses due to fentanyl and other powerful opioids

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Did HC Wainwright Downgrade Addex Therapeutics

Last week, Addex Therapeutics Ltd (NASDAQ:ADXN) terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow rate of patient recruitment. Addex is suspending its financial guidance. Hence HC Wainwright downgraded its rating to Neutral from Buy without a price target, as dipraglurant…

Benzinga

Addex Stops Parkinson's-Associated Dyskinesia Trial - Read Here Why

Addex Therapeutics Ltd (NASDAQ:ADXN) has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients. Data readout from the trial was expected in 1H of 2023. The company attributes this to the consequences of COVID-19-related patient concerns about participation in studies, staffing…

Benzinga

Indivior Positioned To Profit If Aelis Farma's Study Of Cannabis Use Disorder Succeeds

Indivior PLC (OTCPK:INVVY) (LON:INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD).

Tribune News Service

Can a monthly injection be the key to curbing addiction? These experts say yes

OAKLAND, Calif. — Dr. Andrew Herring has a clear goal walking into every appointment with patients seeking medication to treat an opioid use disorder: persuade them to get an injection of extended-release buprenorphine.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Indivior Study Shows Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression In Chronic Opioid Users

Indivior PLC (OTCPK:INVVY) (LON:INDV) published modeling data examining the competitive interaction between buprenorphine, a treatment for opioid use disorder, and fentanyl, a potent synthetic opioid, to better understand how buprenorphine can reduce fentanyl-induced respiratory depression.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the London Stock Exchange

190 stories

LSE

168 stories

the National Health and Medical Research Council

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

the District of Columbia

81 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.